CMPS
COMPASS Pathways plc
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
COMPASS Pathways plc
Expected move
InputsNext report
Last report
—
Largest filed tie
0
filed ties
13F top-10 QoQ
Top fund weight
—
No other changes.
No other changes.
No peers for COMPASS Pathways plc yet.
No peers for COMPASS Pathways plc yet.
Annual filing, covered
10-K parsed · Mar 24 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 24 '26
Supply-chain ties, covered
None disclosed
Fund holders, covered
No N-PORT holders
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tall tick = annual report · Source: EDGAR
No thesis.
COMPASS Pathways plc
11.57
−0.62 · −5.09%
post 11.62 +0.43%
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
| Manager | Value | % base | |
|---|---|---|---|
| Deep Track Capital | $172.1M | 12.57% | 0.00% |
| RTW | $151.4M | 11.06% | +0.65% |
| BIT Capital | $89.8M | 6.56% | +81.85% |
| Tang | $70.8M | 5.17% | +24.93% |
| Two Sigma | $63.3M | 4.62% | +73.04% |
| Manager | Value | % base | |
|---|---|---|---|
| Deep Track Capital | $172.1M | 12.57% | 0.00% |
| RTW | $151.4M | 11.06% | +0.65% |
| BIT Capital | $89.8M | 6.56% | +81.85% |
| Tang | $70.8M | 5.17% | +24.93% |
| Two Sigma | $63.3M | 4.62% | +73.04% |
Bull1
Bear2
Expected move
Inputsspot 11.57exp Nov 20ATM strike 12ATM straddle 1.80IV 79%